# US 10,865,247 B2 · Anti-human CD69 antibody, and use thereof for medical purposes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,865,247 B2 - Document ID: US10865247B2 - Status: Granted - Kind: B2 - Application number: 16/796,481 - Filed: 2020-02-20 - Published: 2020-06-25 - Granted: 2020-12-15 - Earliest claimed: 2012-04-23 - Assignees: GeneFrontier Corporation; National University Corporation Chiba University - Applicants: GeneFrontier Corporation; National University Corporation Chiba University - Inventors: Kanehisa Kojoh; Akira Miyakoshi; Shizue Katoh; Kumiko Tsuihiji; Yuki Hayami; Mikiko Nakamura; Toshinori Nakayama; Chiaki Iwamura - Web page: https://patentgrep.com/patent/US10865247B2 ## CPC - C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72} - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61K 2039/505: {comprising antibodies} - C07K 2317/21: from primates, e.g. man - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/55: Fab or Fab' - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody. ## Claims ### Claim 1 An antibody comprising a light chain variable region and a heavy chain variable region, wherein the antibody binds to an epitope of the human CD69, wherein the light chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 7; CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 19 or 20, and wherein the heavy chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 10; CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and CDR3 comprising the amino acid sequence of SEQ ID NO: 12. ### Claim 2 (depends on 1) The antibody according to claim 1, wherein the antibody cross-reacts with mouse CD69. ### Claim 3 (depends on 1) The antibody according to claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23, 27 or 28, and wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24. ### Claim 4 (depends on 1) The antibody according to claim 1, wherein the epitope comprises the amino acid sequence of SEQ ID NO: 33 and is less than or equal to 12 amino acid residues. ### Claim 5 (depends on 4) The antibody according to claim 4, wherein the epitope is a continuous partial sequence of the amino acid sequence of SEQ ID NO: 30. ### Claim 6 (depends on 4) The antibody according to claim 4, wherein the epitope consists of the amino acid sequence of SEQ ID NO: 35 or 36. ### Claim 7 An antibody comprising a light chain variable region and a heavy chain variable region, wherein the antibody binds to an epitope of the human CD69, wherein the light chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 7; CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 19 or 20, and wherein the heavy chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 10; CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and CDR3 comprising the amino acid sequence of SEQ ID NO: 12 wherein 1 to 3 amino acid residues are substituted at 1 to 3 positions selected from the group consisting of the 1st, 4th, and 5th positions in the amino acid sequences of SEQ ID NO: 9, 19 or 20, and wherein the amino acid sequence of CDR3 in the light chain variable region comprises: glutamine or glycine at the 1st position; aspartic acid or threonine at the 4th position; and serine or threonine at the 5th position. ### Claim 8 (depends on 7) The antibody according to claim 7, wherein the amino acid sequence of the 1st position to the 5th position of CDR3 in the light chain variable region is QSYDS, QSYTS or GSYTT. ### Claim 9 (depends on 7) The antibody according to claim 7, wherein the antibody cross-reacts with mouse CD69. ### Claim 10 (depends on 7) The antibody according to claim 7, wherein the epitope comprises the amino acid sequence of SEQ ID NO: 33 and is less than or equal to 12 amino acid residues. ### Claim 11 (depends on 10) The antibody according to claim 10, wherein the epitope is a continuous partial sequence of the amino acid sequence of SEQ ID NO: 30. ### Claim 12 (depends on 10) The antibody according to claim 10, wherein the epitope consists of the amino acid sequence of SEQ ID NO: 35 or 36.